Drug intelligence / Profile preview

norstictic acid

Development stage: Unknown
Lead developer: University of Utah College of Pharmacy

Overview

norstictic acid: sourced facts only. name: "Of these, norstictic acid was the most potent inhibitor of PHPT1 activity with an IC50 value of 7.9 ± 0.8 μM under our assay conditions." [PMID:35859860]; target: "Of these, norstictic acid was the most potent inhibitor of PHPT1 activity with an IC50 value of 7.9 ± 0.8 μM under our assay conditions." [PMID:35859860]; developer: "Department of Medicinal Chemistry, University of Utah College of Pharmacy, Salt Lake City, Utah 84112, United States." [PMID:35859860]

Targets

PHPT1 (Phosphohistidine phosphatase 1)

Beyond the preview

Go deeper on norstictic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on norstictic acid.